|Videos|July 21, 2020

Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

CAR T-cell therapy ​has demonstrated encouraging activity in adults with relapsed/refractory non-Hodgkin lymphoma and pediatric patients with relapsed/refractory acute lymphoblastic leukemia, says Shaughnessy

​Several ongoing studies are​ evaluating CAR T-cell therapy ​in multiple myeloma and other ​types of lymphoma, explains Shaughnessy. Moreover, the encouraging results observed thus far ​suggest that CAR T-cell therapy will receive regulatory approval in additional indications in the future.

Beyond the hematologic space, CAR T-cell therapy could ​have utility in solid tumors, Shaughnessy concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Latest CME